- Conditions
- Renal Impairment
- Interventions
- MBX 2109
- Drug
- Lead sponsor
- MBX Biosciences
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 25 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2025
- U.S. locations
- 3
- States / cities
- Miami, Florida • Tampa, Florida • Minneapolis, Minnesota
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–8
of 8
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Postbariatric Hypoglycemia
- Interventions
- MBX 1416 (Part A), MBX 1416 (Part B), Placebo, MBX 1416 (Part C)
- Drug
- Lead sponsor
- MBX Biosciences
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 69 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2024
- U.S. locations
- 1
- States / cities
- Chula Vista, California
- Conditions
- Obesity
- Interventions
- MBX 4291, Placebo
- Drug
- Lead sponsor
- MBX Biosciences
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 124 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2026
- U.S. locations
- 4
- States / cities
- Doral, Florida • Lexington, Kentucky • Kansas City, Missouri + 1 more
- Conditions
- Hypoparathyroidism
- Interventions
- Canvuparatide, Placebo
- Drug · Other
- Lead sponsor
- MBX Biosciences
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 160 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 12
- States / cities
- Homestead, Florida • Metairie, Louisiana • Las Vegas, Nevada + 9 more
- Conditions
- Hypoparathyroidism
- Interventions
- 400 µg of MBX 2109 once-weekly by subcutaneous injection, 200-1600 µg of MBX 2109 once-weekly by subcutaneous injection
- Drug
- Lead sponsor
- MBX Biosciences
- Industry
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 17
- States / cities
- Miami, Florida • Macon, Georgia • Jackson, Mississippi + 14 more
- Conditions
- Postbariatric Hypoglycemia
- Interventions
- MBX 1416 (INN imapextide)
- Drug
- Lead sponsor
- MBX Biosciences
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2026
- U.S. locations
- 4
- States / cities
- Aurora, Colorado • Morehead City, North Carolina • Knoxville, Tennessee + 1 more
- Conditions
- Hypoparathyroidism
- Interventions
- MBX 2109, Placebo
- Drug · Other
- Lead sponsor
- MBX Biosciences
- Industry
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 64 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2025
- U.S. locations
- 27
- States / cities
- Sacramento, California • Jacksonville, Florida • Miami, Florida + 22 more
- Conditions
- Healthy
- Interventions
- MBX 2109 (Part A), MBX 2109 (Part B), Placebo
- Drug
- Lead sponsor
- MBX Biosciences
- Industry
- Eligibility
- 21 Years to 60 Years
- Enrollment
- 76 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2023
- U.S. locations
- 2
- States / cities
- Dallas, Texas • Madison, Wisconsin